Working draft — Scientific review: pending | Regulatory review: pending | Not for external clinical or promotional use without independent verification

Request Scientific Information

Healthcare professionals, prescribers and researchers may contact NW PharmaTech to request scientific information, evidence summaries, research collaboration details or educational materials.

Evidence Status

Working draft

Last Reviewed

April 2026

Audience

UK healthcare professionals, researchers, prescribers and informed stakeholders

Verification

References internally cross-checked; independent scientific and regulatory verification pending

Scientific review: PendingRegulatory review: Pending

Version History

Date	Change	Source Update	Reviewer
April 2026	Initial working draft published. 27 indications mapped across core and emerging sections.	All references internally cross-checked against PubMed, NICE, NHS Digital, ONS, disease charity sources. Independent verification pending.	NW PharmaTech Scientific Team (pending independent review)
April 2026	UK epidemiology and burden data layer added for all core indications.	ONS mid-2025 population (69,487,000); NHS Digital APMS 2023/24; disease-specific charity estimates.	NW PharmaTech Scientific Team (pending independent review)
April 2026	Burden cards reworked to map to specific matrix indications with Level 1-3 evidence. Removed broad disease-area cards (Cancer, Chronic Pain, Parkinson's) that could mislead. Added evidence level and matrix indication labels to each card.	No new sources; existing sources re-mapped to indication-specific cards.	NW PharmaTech Scientific Team (pending independent review)

This website is for educational purposes only and is not a substitute for specialist medical advice, diagnosis or treatment. It does not provide access to medicines or prescribing services. References have been internally cross-checked; independent scientific and regulatory verification is pending. CannabinoidEvidence.org